Adjuvant Low Dose Aspirin in Colorectal Cancer

Study ID
NCT02647099

Study type
Interventional

Study phase
Phase 3

Study status
Active, not recruiting

Trial Acronym

ALASCCA

Trial Summary

ALASCCA is a randomized, parallel group, double blind, multicenter, placebo-controlled, biomarker-based study of adjuvant treatment with low dose aspirin in patients with colorectal cancer. Hypothesis is that patients diagnosed with colorectal cancer and somatic mutations in PI3K pathway can significantly improve survival if treated with low dose aspirin.

More informations

Trial Starting Date

Apr 07,2016

Requirements

Gender All
Minimum age 18 Years
Maximum age 80 Years

Enrollement Limit

600